Himeji Medical Center

Himeji 670-8520

3 studies enrolling now · 3 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Drug-Related Side Effects and Adverse Reactions, Nausea, Neoplasm Metastasis, Neoplasms, Vomiting

Studies at this site

• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now